Related references
Note: Only part of the references are listed.Comparison of Disease Activity in SPMS and PPMS in the Context of Multicenter Clinical Trials
Rotem Orbach et al.
PLOS ONE (2012)
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Owain W. Howell et al.
BRAIN (2011)
Potassium channel blocker, 4-aminopyridine-3-methanol, restores axonal conduction in spinal cord of an animal model of multiple sclerosis
Gary Leung et al.
EXPERIMENTAL NEUROLOGY (2011)
Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis
Sven G. Meuth et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis
J. Theodore Phillips et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
P. Vermersch et al.
NEUROLOGY (2011)
Impact of Walking Impairment in Multiple Sclerosis Perspectives of Patients and Care Partners
Nicholas G. LaRocca
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2011)
A Phase 3 Trial of Extended Release Oral Dalfampridine in Multiple Sclerosis
Andrew D. Goodman et al.
ANNALS OF NEUROLOGY (2010)
A Gradient of Neuronal Loss and Meningeal Inflammation in Multiple Sclerosis
Roberta Magliozzi et al.
ANNALS OF NEUROLOGY (2010)
Contribution of impaired mobility to patient burden in multiple sclerosis
Matthew H. Sutliff
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Possible clinical outcome measures for clinical trials in patients with multiple sclerosis
Myla D. Goldman et al.
Therapeutic Advances in Neurological Disorders (2010)
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Josa M. Frischer et al.
BRAIN (2009)
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
Andrew D. Goodman et al.
LANCET (2009)
Assessing disability progression with the Multiple Sclerosis Functional Composite
R. A. Rudick et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS
F. Sellebjerg et al.
NEUROLOGY (2009)
Lymphoid chemokines in chronic neuroinflammation
Francesca Aloisi et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls
Myla D. Goldman et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Measuring deterioration in international classification of functioning domains of people with multiple sclerosis who are ambulatory
Jaana Paltamaa et al.
PHYSICAL THERAPY (2008)
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology
Roberta Magliozzi et al.
BRAIN (2007)
Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis
J. J. Kragt et al.
MULTIPLE SCLEROSIS JOURNAL (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite
ELJ Hoogervorst et al.
MULTIPLE SCLEROSIS (2004)
Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite
J Hobart et al.
MULTIPLE SCLEROSIS JOURNAL (2004)
A controlled trial of natalizumab for relapsing multiple sclerosis.
DH Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
JA Cohen et al.
NEUROLOGY (2002)
Share Paper
